17,261 trials
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Primary: Number of Participants With Treatment-emergent Adverse Event (TEAEs) — 10; 10 Participants
Myelodysplastic Syndrome · Chronic Myelomonocytic Leukemia · Small Lymphocytic Lymphoma
Primary: Percentage of Participants Who Are Able to Stop Prophylactic Tacrolimus (D90 Cohort) — 33 Participants
Non-small Cell Lung Cancer
Primary: Percentage of Participants Who Developed Grade 3 or Higher Pneumonitis — 8.0; 6.9 Percentage of Participants
Fragile X Tremor/Ataxia Syndrome
Primary: FXTAS Rating Scale Score — 45.8 score on a scale
Raynaud's Phenomenon Secondary to Connective Tissue Disease
Primary: Raynaud's Symptom Severity (Change From Baseline) — -20.19; -18.63 score on a scale
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) — -1.20; -1.26 Percentage of HbA1c
Urothelial Carcinoma
Primary: Bladder Tumor Recurrence Rate — 41.37 percentage of subjects
Fetal Alcohol Spectrum Disorders
Primary: Elicited Imitation Memory Task - Short Delay Memory Measure: 6 Months — 0.252; 0.183 change in percentage correct
Kaposi Sarcoma · Sarcoma, Kaposi
Primary: Number of Participants With Grades 1-4 Adverse Events That Are Possibly, Probably, and/or Definitely Attributed to Pomalidomide — 21; 10; 1; 0 Participants
Idiopathic Pulmonary Fibrosis
Primary: The Change From Baseline in Forced Vital Capacity (FVC) at 12 Weeks — -77.70; 2.72; -95.62; 6.10 Milliliter
Leukemia · Lymphoma
Primary: Number of Transplant Recipients With Successful Engraftment — 70 Participants
T Cell Lymphoma
Primary: Number of Participants With and Without Dose Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Pre Diabetes
Primary: Progression From Prediabetes to Diabetes — 0; 1 Participants
Type 1 Diabetes Mellitus
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) — 0.04; -0.13 Percentage of HbA1c
Healthy
Primary: Post Infusion Recovery of Test Platelets at End of Storage (Day 7) — 39.5; 57.8; 39.1; 60.4 percentage of infused platelets